October 9th, 2020
Neurocarrus and the National Institutes of Neurologic Disease and Stroke (NINDS) have agreed to enter N-001 into their internal testing program for new candidate pain therapeutics. This agreement further expands federal nondilutional investment in Neurocarrus.
October 5th, 2020
SBIR/STTR award from Nebraska Department of Economic Development. This additional nondilutional investment supports advances in N-001 manufacturing.
September 30th, 2020
Neurocarrus is happy to announce receipt of a Phase I National Institutes of Health (NIH) Small Business Innovation Research (SBIR) award for preclinical development of its candidate human pain drug N-001. This nondilutional investment supports expanded testing of N-001 in collaboration with doctors at Stanford University and VA Palo Alto Medical Center.
April 28, 2020
Neurocarrus has an exclusive license for technology described in Patent No. 10,633,643. Having issued, Neurocarrus can now license this patent as a revenue stream. A divisional patent application will be filed that will further expand the value to Neurocarrus.